<DOC>
	<DOCNO>NCT01098435</DOCNO>
	<brief_summary>The purpose study evaluate safety daily dose RDC-0313 ( ALKS 33 ) compare placebo adult binge-eating disorder ( BED ) . An additional objective explore efficacy RDC-0313 treatment comparison placebo adult binge-eating disorder .</brief_summary>
	<brief_title>ALK33-101 : A Study RDC-0313 ( ALKS 33 ) Adults With Binge Eating Disorder</brief_title>
	<detailed_description>Following screening , eligible subject randomize 1:1 ratio RDC-0313 ( ALKS 33 ) match placebo . Once-daily at-home dose begin randomization continue 6 week . There 8 study visit 12-week study period . On ongoing basis , subject complete take-home binge diary design record number binge-eating episode ( binge episode ) binge-eating day ( binge day , day least 1 binge occur ) , well snack meal consume daily 7-day period .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Binge-Eating Disorder</mesh_term>
	<mesh_term>Feeding Eating Disorders</mesh_term>
	<mesh_term>Bulimia</mesh_term>
	<mesh_term>ALKS-33</mesh_term>
	<criteria>Meet Diagnostic Statistical Manual Mental Disorders , 4th Edition , text revise ( DSMIVTR ) criteria diagnosis binge eat disorder ( BED ) Display great equal 3 binge eating day per week Body mass index ( BMI ) great equal 30 kg/m2 Age 18 year old Women childbearing potential must agree use approve method birth control duration study Concurrent symptom bulimia nervosa anorexia nervosa Suicidal ideation DSMIVTR diagnosis substance abuse dependence ( except nicotine caffeine ) within 6 month prior randomization Positive urine toxicological screen benzodiazepine , opioids , amphetamine/methamphetamine , cocaine screen randomization Women pregnant breastfeed Participation psychological weight loss intervention BED initiate within 3 month prior screen Clinically unstable medical disease History hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) History seizure , include clinically significant febrile seizure childhood Current anticipate need prescribe opioid medication study period Use psychotropic medication ( hypnotic ) Participation clinical trial pharmacological agent within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Binge eat disorder</keyword>
	<keyword>RDC-0313</keyword>
</DOC>